Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KEO Trial

NCT03325465 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03325465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03325465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KEO Trial
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Withdrawn
Start date
January 22, 2018
Completion date
November 7, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck